Dr. Byoung Chul Cho

Scientific Advisory Board

Dr. Byoung Chul Cho is a medical oncologist and Professor in the Division of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine and Chief of Lung Cancer Center at Yonsei Cancer Center. He directs Yuhan-Yonsei lung cancer clinical and translational medicine center as well as Yonsei New Il Han Institute for Integrative Cancer Research.

Dr. Cho is a world-renowned expert in the field of translational oncology, responsible for 60+ early clinical trials to late phase clinical trials, with 23 phase 1 clinical trials throughout the past three years. He played a monumental role in developing repotrectinib, lazertinib, amivantamab, and other targeted- and immuno-therapies, many of which were acknowledged for breakthrough therapy designation and FDA approval. His Daan Cancer Laboratory focuses on deciphering the immune microenvironment to identify novel immunotherapy target and design combination strategy, evaluating efficacy of novel cancer therapeutics using patient-derived preclinical models, as well as understanding resistance mechanisms to targeted therapy in lung cancer.

Dr. Cho and over 100 members of his laboratory also spearhead the new paradigm in translational medicine, collaborating with national and international biotech companies as well as providing novel treatment approaches for lung cancer patients. Dr. Cho has also published over 250 journals throughout his career, many of which were highlighted in Lancet Oncology, Cancer Discovery, Nature Medicine, and the New England Journal of Medicine.

Dr. Cho has been the recipient of numerous awards and honors through his dedication to the field of cancer research, including the 21st Wunsch Medical Award, Boryeong Research Award from the Korean Society Medical Oncology, the 51st Yuhan Medical Award (Excellence Award), and the 3rd Yongwoon Medical Award. He has also served on over 30 steering committees and advisory boards in all parts of the world.